Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience

Por Semrad, Thomas J., Gandara, David R., Lara, Primo N.
Publicado em 2011

Genotyping and Genomic Profiling of Non–Small-Cell Lung Cancer: Implications for Current and Future Therapies

Por Li, Tianhong, Kung, Hsing-Jien, Mack, Philip C., Gandara, David R.
Publicado em 2013

Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819

Por Redman, Mary W., Crowley, John J., Herbst, Roy S., Hirsch, Fred R., Gandara, David R.
Publicado em 2012

Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines

Por Holland, William S., Chinn, Danielle C., Lara, Primo N., Gandara, David R., Mack, Philip C.
Publicado no J Cancer Res Clin Oncol (2014)

Non–Small Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy

Por Carbone, David P., Gandara, David R., Antonia, Scott J., Zielinski, Christoph, Paz-Ares, Luis
Publicado no J Thorac Oncol (2015)

Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics

Por Gandara, David R., Hammerman, Peter S., Sos, Martin L., Lara, Primo N., Hirsch, Fred R.
Publicado no Clin Cancer Res (2015)

Aberrant Regulation of the MRP3 Gene in Non-Small Cell Lung Carcinoma

Por Mahaffey, Christopher M., Mahaffey, Nichole C., Holland, William, Zhang, Hongqiao, Gandara, David R., Mack, Philip C., Forman, Henry Jay
Publicado em 2012

A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors

Por Iqbal, Syma, Lenz, Heinz-Josef, Gandara, David R., Shibata, Stephen I., Groshen, Susan, Synold, Timothy W., Newman, Edward M.
Publicado em 2013

Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy

Por Holland, William S., Tepper, Clifford G., Pietri, Jose E., Chinn, Danielle C., Gandara, David R., Mack, Philip C., Lara, Primo N.
Publicado no Cancer Chemother Pharmacol (2011)

Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: A phase II Southwest Oncology Group study (S0339)

Por Davies, Angela M., Chansky, Kari, Lara, Primo N., Gumerlock, Paul H., Crowley, John, Albain, Kathy S., Vogel, Stanley J., Gandara, David R.
Publicado em 2009

Phase II study of cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (NCI # 7097)

Por Ramalingam, Suresh S., Belani, Chandra P., Mack, Philip C., Vokes, Everett E., Longmate, Jeffrey, Govindan, Ramaswamy, Koczywas, Marianna, Ivy, S. Percy, Gandara, David R.
Publicado em 2010

Phase II Study of Aflibercept (VEGF-Trap) in Patients with Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial

Por Twardowski, Przemyslaw, Stadler, Walter M, Frankel, Paul, Lara, Primo N, Ruel, Christopher, Chatta, Gurkamal, Heath, Elisabeth, Quinn, David I, Gandara, David R
Publicado em 2010

A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium Study

Por Lara, Primo N., Longmate, Jeff, Evans, Christopher P., Quinn, David I., Twardowski, Przemyslaw, Chatta, Gurkamal, Posadas, Edwin, Stadler, Walter, Gandara, David R.
Publicado em 2009

Algorithm for Codevelopment of New Drug-Predictive Biomarker Combinations: Accounting for Inter- and Intrapatient Tumor Heterogeneity

Por Gandara, David R., Li, Tianhong, Lara, Primo N., Mack, Philip C., Kelly, Karen, Miyamoto, Suzanne, Goodwin, Neal, Beckett, Laurel, Redman, Mary W.
Publicado em 2012

A Phase II study of VEGF Trap (Aflibercept, NSC 724770) in Patients with MDS: A California Cancer Consortium Study

Por Kirschbaum, Mark, Frankel, Paul, Synold, Timothy W., Zain, Jasmine, Claxton, David, Tuscano, Joseph, Newman, Edward M., Gandara, David R., Lara, Primo N.
Publicado no Br J Haematol (2016)

Common arm comparative outcomes analysis of phase III trials of cisplatin + irinotecan vs. cisplatin + etoposide in extensive stage small cell lung cancer: Final patient-level resu...

Por Lara, Primo N., Chansky, Kari, Shibata, Taro, Fukuda, Haruhiko, Tamura, Tomohide, Crowley, John, Redman, Mary W., Natale, Ronald, Saijo, Nagahiro, Gandara, David R
Publicado em 2010

Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin

Por Tarhini, Ahmad A., Frankel, Paul, Margolin, Kim A., Christensen, Scott, Ruel, Christopher, Shipe-Spotloe, Janice, Gandara, David R, Chen, Alice, Kirkwood, John M.
Publicado em 2011

SWOG S0722: Phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM)

Por Ignatius Ou, Sai-Hong, Moon, James, Garland, Linda L., Mack, Philip C., Testa, Joseph R., Tsao, Anne S., Wozniak, Antoniette J., Gandara, David R.
Publicado no J Thorac Oncol (2015)

Disease control rate at 8 weeks predicts subsequent survival in platinum-treated extensive stage small cell lung cancer: Results from the Southwest Oncology Group (SWOG) database

Por Lara, Primo N., Moon, James, Redman, Mary W., Semrad, Thomas J., Kelly, Karen, Allen, Jeffrey, Gitlitz, Barbara, Mack, Philip C., Gandara, David R.
Publicado no Clin Lung Cancer (2015)

A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial

Por Li, Tianhong, Christensen, Scott D., Frankel, Paul H., Margolin, Kim A., Agarwala, Sanjiv S., Luu, Thehang, Mack, Philip C., Lara, Primo N., Gandara, David R.
Publicado em 2010